Lead Product(s): Antibodies
Therapeutic Area: Oncology
Highest Development Status: Undisclosed Product Type: Large molecule
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 30, 2020
The agreement, for an undisclosed amount, includes process development and conjugation of two antibodies in BioInvent's development labs with work expected to start in May 2020.